Literature DB >> 24036228

Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission.

Benjamin G Luttge1, Prashant Panchal1, Vinita Puri1, Mary Ann Checkley1, Eric O Freed2.   

Abstract

The Pro-Ser-Ala-Pro (PSAP) motif in the p2 domain of feline immunodeficiency virus (FIV) Gag is required for efficient virus release, virus replication, and Gag binding to the ubiquitin-E2-variant (UEV) domain of Tsg101. As a result of this direct interaction, expression of an N-terminal fragment of Tsg101 containing the UEV domain (referred to as TSG-5') inhibits FIV release. In these respects, the FIV p2(Gag) PSAP motif is analogous to the PTAP motif of HIV-1 p6(Gag). To evaluate the feasibility of a late domain-targeted inhibition of virus replication, we created an enriched Crandell-Rees feline kidney (CRFK) cell line (T5'(hi)) that stably expresses high levels of TSG-5'. Here we show that mutations in either the V3 loop or the second heptad repeat (HR2) domain of the FIV envelope glycoprotein (Env) rescue FIV replication in T5'(hi) cells without increasing FIV release efficiency. TSG-5'-resistance mutations in Env enhance virion infectivity and the cell-cell spread of FIV when diffusion is limited using a semi-solid growth medium. These findings show that mutations in functional domains of Env confer TSG-5'-resistance, which we propose enhances specific infectivity and the cell-cell transmission of virus to counteract inefficient virus release. This article is part of a Special Issue entitled: Viral Membrane Proteins-Channels for Cellular Networking.
© 2013.

Entities:  

Keywords:  AIDS; Cell-to-cell virus transmission; ESCRT; FIV; HIV-1; Late domain; TSG-5' resistance; Tsg101

Mesh:

Substances:

Year:  2013        PMID: 24036228      PMCID: PMC3943682          DOI: 10.1016/j.bbamem.2013.08.020

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  94 in total

1.  Identification and structural characterization of the ALIX-binding late domains of simian immunodeficiency virus SIVmac239 and SIVagmTan-1.

Authors:  Qianting Zhai; Michael B Landesman; Howard Robinson; Wesley I Sundquist; Christopher P Hill
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

Review 2.  FIV infection of the domestic cat: an animal model for AIDS.

Authors:  B J Willett; J N Flynn; M J Hosie
Journal:  Immunol Today       Date:  1997-04

3.  Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids.

Authors:  Jörg Zielonka; Daniela Marino; Henning Hofmann; Naoya Yuhki; Martin Löchelt; Carsten Münk
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

4.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 5.  Lessons from the cat: development of vaccines against lentiviruses.

Authors:  Stephen P Dunham
Journal:  Vet Immunol Immunopathol       Date:  2006-05-05       Impact factor: 2.046

Review 6.  FIV: from lentivirus to lentivector.

Authors:  Dyana T Saenz; Eric M Poeschla
Journal:  J Gene Med       Date:  2004-02       Impact factor: 4.565

7.  Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus.

Authors:  T R Phillips; C Lamont; D A Konings; B L Shacklett; C A Hamson; P A Luciw; J H Elder
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association.

Authors:  Stefanie Jäger; Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

Review 9.  The molecular biology of feline immunodeficiency virus (FIV).

Authors:  Julia C Kenyon; Andrew M L Lever
Journal:  Viruses       Date:  2011-11-09       Impact factor: 5.048

Review 10.  Pharmacological inhibition of feline immunodeficiency virus (FIV).

Authors:  Hakimeh Mohammadi; Dorothee Bienzle
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

View more
  5 in total

1.  Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Authors:  Rachel Van Duyne; Lillian S Kuo; Phuong Pham; Ken Fujii; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

2.  Alix-Mediated Rescue of Feline Immunodeficiency Virus Budding Differs from That Observed with Human Immunodeficiency Virus.

Authors:  Claudia Del Vecchio; Michele Celestino; Marta Celegato; Giorgio Palù; Cristina Parolin; Fadila Bouamr; Arianna Calistri
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

3.  HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.

Authors:  Terumasa Ikeda; Menelaos Symeonides; John S Albin; Ming Li; Markus Thali; Reuben S Harris
Journal:  PLoS Pathog       Date:  2018-04-20       Impact factor: 6.823

Review 4.  Importance of Viral Late Domains in Budding and Release of Enveloped RNA Viruses.

Authors:  Lisa Welker; Jean-Christophe Paillart; Serena Bernacchi
Journal:  Viruses       Date:  2021-08-06       Impact factor: 5.048

5.  HIV-1 mutates to evade IFITM1 restriction.

Authors:  Shilei Ding; Qinghua Pan; Shan-Lu Liu; Chen Liang
Journal:  Virology       Date:  2014-02-20       Impact factor: 3.616

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.